





## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

## EQA round: TDM1/19 - Therapeutic Drugs

Dead line: 12.04.2019

Test	[unit]	Comparability						Traceability															
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(87) Ethosuximide</b>					8							8	7	88%									0
Samples and groups	[µmol/L]																						
<b>Sample A1</b>		458	31	6,8	8		CVP	458	24	24%	348	568	8	7	88%								0
(999) another manufacturer		465	21	4,6	6	0							6										
Other					2	0							2										
							1x 149, 1x 998																
<b>Sample B1</b>		482	24	4,9	8		CVP	482	18	24%	366	598	8	8	100%								0
(999) another manufacturer		482	11	2,3	6	0							6										
Other					2	0							2										
							1x 149, 1x 998																
<b>(88) Valproic acid</b>					84								84	82	98%								0
Samples and groups	[µmol/L]																						
<b>Sample A1</b>		519	32	6,1	84		CVP	519	8,5	20%	415	623	84	83	99%								0
(1) Abbott		498	27	5,4	28	0							28										
(29) Siemens (DPC)		531	33	6,1	8	0							8										
(58) Beckman Coulter (Olympus)		563	39	7,0	8	0							8										
(60) Roche		519	24	4,6	29	0							29										
(179) Siemens (Bayer)		547	13	2,4	7	0							7										
Other					4	0							4										
							2x 12, 1x 75, 1x 149																
<b>Sample B1</b>		239	17	7,2	84		CVP	239	4,6	20%	191	287	84	83	99%								0
(1) Abbott		227	12	5,3	28	0							28										
(29) Siemens (DPC)		235	3,0	1,3	8	0							8										
(58) Beckman Coulter (Olympus)		254	16	6,2	8	0							8										
(60) Roche		242	12	5,1	29	0							29										
(179) Siemens (Bayer)		261	16	6,2	7	0							7										
Other					4	0							4										
							2x 12, 1x 75, 1x 149																
<b>Set of samples 2</b>																							
<b>(89) Amicacin</b>					30								30	25	83%								0
Samples and groups	[µmol/L]																						
<b>Sample A2</b>		6,42	0,92	14	30		CVP	6,42	0,41	20%	5,13	7,71	30	25	83%								0
(60) Roche		6,34	0,80	13	19	0							19										
Other					11	0							11										
							4x 1, 1x 12, 1x 58, 2x 149, 3x 166																
<b>Sample B2</b>		22,4	1,2	5,4	30		CVP	22,4	0,54	20%	17,9	26,9	30	28	93%								0
(60) Roche		22,5	1,3	5,8	19	0							19										
Other					11	0							11										
							4x 1, 1x 12, 1x 58, 2x 149, 3x 166																
<b>(90) Gentamicin</b>					59								59	54	92%								0
Samples and groups	[µmol/L]																						
<b>Sample A2</b>		28,3	5,2	18	59		CVP	28,3	1,7	31%	19,5	37,1	59	54	92%								0
(1) Abbott		29,0	1,9	6,7	25	0							25										
(60) Roche		24,7	5,3	22	22	0							22										
(179) Siemens (Bayer)		32,6	6,3	19	6	0							6										
Other					6	0							6										
							3x 12, 3x 58																
<b>Sample B2</b>		13,6	1,6	12	59		CVP	13,6	0,51	31%	9,38	17,9	59	59	100%								0

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

## EQA round: TDM1/19 - Therapeutic Drugs

Dead line: 12.04.2019

Test	[unit]	Comparability					Traceability																	
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>		
<b>(90) Gentamicin</b>					59							59	54	92%									0	
--- Samples and groups ---	[µmol/L]																							
<b>Sample B2</b>		13,6	1,6	12	59	CVP	13,6	0,51	31%	9,38	17,9	59	59	100%									0	
(1) Abbott		14,3	0,93	6,5	25							25												
(60) Roche		12,1	1,5	13	22							22												
(179) Siemens (Bayer)		14,6	1,4	9,7	6							6												
Other					6							6												
							3x 12, 3x 58																	
<b>(92) Vankomycin</b>					61							61	60	98%									0	
--- Samples and groups ---	[µmol/L]																							
<b>Sample A2</b>		31,4	3,5	11	61	CVP	31,4	1,1	28%	22,6	40,2	61	60	98%									0	
(1) Abbott		31,2	1,2	3,8	26							26												
(60) Roche		33,8	4,1	12	24							24												
(179) Siemens (Bayer)		25,8	0,62	2,4	6							6												
Other					5							5												
							2x 12, 2x 58, 1x 149																	
<b>Sample B2</b>		21,8	2,6	12	61	CVP	21,8	0,82	28%	15,6	28	61	60	98%									0	
(1) Abbott		21,6	0,85	3,9	26							26												
(60) Roche		23,6	2,9	12	24							24												
(179) Siemens (Bayer)		18,2	0,30	1,6	6							6												
Other					5							5												
							2x 12, 2x 58, 1x 149																	
<b>(93) Methotrexate</b>					12							12	9	75%									0	
--- Samples and groups ---	[µmol/L]																							
<b>Sample A2</b>		0,568	0,06	12	12	CVP	0,568	0,049	30%	0,397	0,739	12	10	83%									0	
(1) Abbott		0,570	0,03	5,2	8							8												
Other					4							4												
							1x 60, 1x 126, 2x 999																	
<b>Sample B2</b>		1,72	0,40	24	12	CVP	1,72	0,29	30%	1,2	2,24	12	9	75%									0	
(1) Abbott		1,85	0,24	13	8							8												
Other					4							4												
							1x 60, 1x 126, 2x 999																	

st\_kn\_np

End of report

Printed: 18.04.2019